ReviewNPJ breast cancer2018
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer.
Marie-Laure Tanguy et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this paperpooled itcites it